Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FRA:R9Z'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -90.64 Med: -48.19 Max: -21.97
Current: -23.65
During the past 5 years, ImmuneOnco Biopharmaceuticals (Shanghai)'s highest Return-on-Tangible-Asset was -21.97%. The lowest was -90.64%. And the median was -48.19%.
FRA:R9Z's Return-on-Tangible-Asset is ranked better than 59.83% of 1414
companies
in the Biotechnology industry
Industry Median: -36.16
vs FRA:R9Z: -23.65
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
ImmuneOnco Biopharmaceuticals (Shanghai) Return-on-Tangible-Asset Related Terms
ImmuneOnco Biopharmaceuticals (Shanghai) Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:R9Z vs VRTX, REGN, RVMD: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuneOnco Biopharmaceuticals (Shanghai) Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -14.14% mean?
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) has a Return-on-Tangible-Asset of -14.14% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. According to the industry distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #568 out of 1414 companies in the Biotechnology industry, placing it in the top 40.2%.
Is ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Asset too high?
ImmuneOnco Biopharmaceuticals (Shanghai)'s current Return-on-Tangible-Asset is -14.14%. Based on the distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #568 out of 1414 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ImmuneOnco Biopharmaceuticals (Shanghai) has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does ImmuneOnco Biopharmaceuticals (Shanghai)'s Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #568 out of 1414 companies for Return-on-Tangible-Asset. This puts ImmuneOnco Biopharmaceuticals (Shanghai) in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. ImmuneOnco Biopharmaceuticals (Shanghai)'s current Return-on-Tangible-Asset is -14.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuneOnco Biopharmaceuticals (Shanghai) stock overvalued right now?
ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z) has a current Return-on-Tangible-Asset of -14.14%. The current Return-on-Tangible-Asset is -14.14%. ImmuneOnco Biopharmaceuticals (Shanghai)'s overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For ImmuneOnco Biopharmaceuticals (Shanghai) (FRA:R9Z), the current Return-on-Tangible-Asset is -14.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
6GF Score
Get the complete analysis for FRA:R9Z
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:R9Z has been successfully added to your 
